Drug Benefit List

DBL Reports

Search the compilation of all issues PDF of all DBL Reports from April 1, 1999 to present (Note: large file) or view separate issues listed below.

November 1, 2017 - Issue #99 PDF
Brief Summary of Drug Review Activities
Highlights of:
Products Originally Reviewed via the CDR
Line Extension Drug Products
Expedited IC Drug Products added
IC Drug Products added
Other Drug Products added
Changes to currently listed products

September 1, 2017 - Issue #98 PDF
Brief Summary of Drug Review Activities
Highlights of Products originally reviewed via the CDR
Highlights of Drug Products added
Highlights of Expedited IC Drug Products added
Highlights of IC Drug Products added
Special Authorization criteria changes
Restricted Benefit cirteria changes

July 1, 2017 - Issue #97 PDF
Brief Summary of Drug Review Activities
Highlights of Products originally reviewed via the CDR
Highlights of Devices added
Highlights of Interchangeable Drug Products added
Highlights of Non-Interchangeable Old Drug Products added

May 1, 2017 - Issue #96 PDF
Brief Summary of Drug Review Activities
Highlights of Products originally reviewed via the CDR
Highlights of Drug products added
Highlights of Interchangeable drug products reviewed
Highlights of Other products reviewed but not added
Special Authorization Criteria Changes

February 1, 2017 - Issue #95 PDF
Brief Summary of Drug Review Activities
Highlights of Products Originally Reviewed via the CDR
Highlights of Interchangeable Drug Products added
Highlights of Other Products Added
Changes in Listing Status
Special Authorization Criteria Changes

November 1, 2016 - Issue #94 PDF
Brief Summary of Drug Review Activities
Highlights of Products Originally Reviewed via the CDR
Highlights of Interchangeable Drug Products Added
Highlights of Other Products Added
Maximum Allowable Cost (MAC) New Category

September 1, 2016 - Issue #93 PDF
Brief Summary of Drug Review Activities
Highlights of Products Originally Reviewed via the CDR
Highlights of Interchangeable Drug Products Added
Highlights of Other Products Added

July 1, 2016 - Issue #92 PDF
Brief Summary of Drug Review Activities
Highlights of Products Originally Reviewed via the CDR
Highlights of Interchangeable Drug Products added
Special Authorization Criteria Changes

May 1, 2016 - Issue #91 PDF
Brief Summary of Drug Review Activities
Highlights of Products Originally Reviewed via the CDR
Highlights of Non-Interchangeable Old Drug Products
Highlights of Line Extension Drug Products Reviewed for the ADBL
Highlights of Other Products Reviewed but Not Added
Highlights of Interchangeable Drug Products Reviewed
Highlights of Other Products Added
Highlights of New Interchangeable Groupings
Special Authorization Criteria Changes

March 1, 2016 - Issue #90 PDF
Brief Summary of Drug Review Activities
Highlights of Products Originally Reviewed via the CDR
Highlights of Devices Added
Highlights of Line Extension Drug Products
Highlights of Other Drug Products Reviewed but Not Added
Highlights of Interchangeable Drug Products Reviewed
Highlights of Natural Health Products Reviewed
Highlights of Change in Listing Status

February 1, 2016 - Issue #89 PDF
Brief Summary of Drug Review Activities
Highlights of Products Originally Reviewed via the CDR
Highlights of Line Extension Products
Highlights of Other Products Reviewed but Not Added
Highlights of Interchangeable Drug Products Reviewed
Special Authorization Criteria Changes
ROBS Review of Growth Hormone Products

November 1, 2015 - Issue #88 PDF
Brief Summary of Drug Review Activities
Highlights of Products Originally Reviewed via the CDR
Highlights of Non-Interchangeable Old Drug Products
Highlights of Line Extension Products
Highlights of Other Products Reviewed but Not Added
Highlights of Interchangeable Drug Products Reviewed
Highlights of Product Listing Changes
Special Authorization Criteria Changes

September 1, 2015 - Issue #87 PDF
Brief Summary of Drug Review Activities
Highlights of Products Originally Reviewed via the CDR
Highlights of Other Products Reviewed but Not Added
Highlights of Interchangeable Drug Products Added
Special Authorization Criteria Changes

July 1, 2015 - Issue #86 PDF
Brief Summary of Drug Review Activities
Highlights of Products Originally Reviewed via the Common Drug Review (CDR)
Highlights of Products Not Added
Highlights of Non-Interchangeable Old Drug Products Added
Highlights of Line Extension Drug Products Reviewed for Addition to the ADBL
Highlights of Interchangeable Drug Products Added
Highlights of Drug Products De-Listed from the ADBL
Special Authorization Criteria Changes

May 1, 2015 - Issue #85 PDF
Brief Summary of Drug Review Activities
Highlights of Products Originally Reviewed via the CDR
Highlights of Line Extension Drug Products Added to the ADBL
Highlights of Natural Health Products Not Added
Special Authorization Criteria Changes

April 1, 2015 - Issue #84 PDF
Brief Summary of Drug Review Activities
Updates to the Manufacturer Submission Requirements
Highlights of Products Originally Reviewed via the CDR
Highlights of Drug Products Added
Highlights of LE Drug Products Added to the ADBL
Highlights of LE Drug Products Not Added to the ADBL
Highlights of IC Drug Products Not Added
Special Authorization Criteria Changes

February 1, 2015 - Issue #83 PDF
Brief Summary of Drug Review Activities
Highlights of Products Originally Reviewed via the Common Drug Review (CDR)
Highlights of Drug Products Added
Highlights of Line Extension Drug Products Reviewed for Addition to the ADBL
Highlights of Interchangeable (IC) Drug Products Added
Highlights of Interchangeable Drug Products Not Added
Highlights of Non-Interchangeable Old Drug Products (NICOD) Not Added
Special Authorization Criteria Changes
Changes in Benefit Status due to product discontinuation

November 1, 2014 - Issue #82 PDF
Brief Summary of Drug Review Activities
Highlights of Interchangeable (IC) Drug Products Added
Highlights of Products Originally Reviewed via the CDR
Highlights of Changes to Currently Listed Products
Highlights of Interchangeable Drug Products Not Added
Highlights of Other Changes to the ADBL

September 1, 2014 - Issue #81 PDF
Brief Summary of Drug Review Activities
Highlights of Products Originally Reviewed via the CDR
Highlights of Entry Interchangeable (IC) Drug Products Added
Highlights of Non-Interchangeable Old Drug Products Not Added
Highlights of Line Extension Drug Products Reviewed by the Expert Committee

July 1, 2014 - Issue #80 PDF
Brief Summary of Drug Review Activities
Highlights of Products Originally Reviewed via the CDR
Highlights of Single Source Drug Products Added
Highlights of Entry Interchangeable (IC) Drug Products Added
Highlights of Non-Interchangeable Old Drug Products Not Added
Highlights of Line Extension Drug Products Added
Aranesp and Eprex Special Authorization Criteria Changes

May 1, 2014 - Issue #79 PDF
Brief Summary of Drug Review Activities
Highlights of Line Extension Drug Products Added
Highlights of Products Originally Reviewed via the CDR
Highlights of Products not Added
Highlights of Non-Interchangeable Old Drug Products Added
Highlights of Entry Interchangeable (IC) Drug Products Added
Vimpat Special Authorization Criteria Changes
Leflunomide Restricted Benefit Criteria Changes

March 1, 2014 - Issue #78 PDF
Brief Summary of Drug Review Activities
Highlights of Line Extension Drug Products Added
Highlights of Products Originally Reviewed via the CDR
Highlights of Expedited IC Products Added
Highlights of IC Drug Products added
Neupogen and Neulasta Special Authorization Criteria Changes
Eliquis Listing Status Update

February 1, 2014 - Issue #77 PDF
Brief Summary of Drug Review Activities
Highlights of Line Extension Drug Products Added
Highlights of Products Originally Reviewed via the CDR
Highlights of IC Drug Products added
Highlights of NICOD Products Added
Highlights of Deferrals
Benefit Coverage and SA Criteria Changes for Osteoporosis Medications
ROBS Review - Beta-Blockers

November 1, 2013 - Issue #76 PDF
Brief Summary of Drug Review Activities
Highlights of Drug Products Added
Highlights of Line Extension Drug Products Added
Highlights of Natural Health Products Added
Highlights of Non-IC Old Drug Products Added
Highlights of Expedited IC Drug Products added
Highlights of Products Originally Reviewed via the CDR
Highlights of IC Drug Products Added
Highlights of SA Criteria Changes

September 1, 2013 - Issue #75 PDF
Brief Summary of Drug Review Activities
Highlights of Line Extension Drug Products Added
Highlights of Expedited IC Drug Products Added
Highlights of Products Originally Reviewed via the CDR
Highlights of Drug Products not Added
Highlights of Criteria Changes
Risk of Hypoglycemia with Anti-diabetic Agents

July 1, 2013 - Issue #74 PDF
Brief Summary of Drug Review Activities
Highlights of New Products Added
Highlights of Products Originally Reviewed via the Common Drug Review (CDR)
Highlights of IC Drug Products Added
Highlights of Natural Health Products Added
Highlights of Line Extension Drug Products Added
Highlights of Criteria Changes

June 1, 2013 - Issue #73 PDF
Brief Summary of Drug Review Activities
Highlights of New Products Added
Highlights of Products Originally Reviewed via the Common Drug Review (CDR)
Highlights of Established IC Drug Products Added
Highlights of Natural Health Products Added
Highlights of Criteria Changes
Follow-up: Pre-Requisite Medications for Biologic Coverage

March 1, 2013 - Issue #72 PDF
Brief Summary of Drug Review Activities
Highlights of Products Originally Reviewed via the Common Drug Review (CDR)
Highlights of Expedited Entry IC Drug Products Added
Highlights of Established IC Drug Products Added
Highlights of Other Additions to the ADBL
Coverage of Controlled Release Oxycodone Drug Products

February 1, 2013 - Issue #71 PDF
Brief Summary of Drug Review Activities
Products Originally Reviewed via the Common Drug Review (CDR)
Highlights of Products Added to the ADBL
Highlights of Entry IC Products Added
Highlights of Established IC Products Added
Highlights of Expedited Entry IC Products Added
Highlights of Motherisk Guidance on Pre-Requisite Medications

November 1, 2012 - Issue #70 PDF
Brief Summary of Drug Review Activities
Highlights of Products Added to the ADBL
Highlights of Entry IC Products Added
Highlights of Expedited Entry IC Products Added
Products of Originally Reviewed via the Common Drug Review (CDR)
Changes in SA Criteria for Clopidogrel

September 1, 2012 - Issue #69 PDF
Brief Summary of Drug Review Activities
Highlights of Products Added
Highlights of IC Products Added
Highlights of Products not Added
Highlights of Changes in MS Drug Coverage
Products Originally Reviewed via the Common Drug Review (CDR)

August 1, 2012 - Issue #68 PDF
Brief Summary of Drug Review Activities
Diabetic Self-management Supplies
Highlights of Products added to the ADBL

May 1, 2012 - Issue #67 PDF
Brief Summary of Drug Review Activities
Products Originally Reviewed via the Common Drug Review (CDR)
Highlights of New IC Groupings
Other Products added to the ADBL

March 1, 2012 - Issue #66 PDF
Brief Summary of Drug Review Activities
Highlights of New Products Added
Highlights of New Interchangeable (IC) Groupings
Highlights of Benefit Coverage and Criteria Changes
Additional Products Originally Reviewed via the Common Drug Review (CDR)

February 1, 2012 - Issue #65 PDF
Brief Summary of Drug Review Activities
Highlights of New IC Groupings
Highlights of Products Not Added
Highlights of IC Products Added
Highlights of Additional Products Added

November 1, 2011 - Issue #64 PDF
Brief Summary of Drug Review Activities
Product Originally Reviewed via the Common Drug Review (CDR)
Highlights of New IC Groupings
Highlights of Products Not Added
Highlights of New Products Added

September 1, 2011 - Issue #63 PDF
Brief Summary of Drug Review Activities
Products Originally Reviewed via the Common Drug Review (CDR)
Highlights of New Products Added
Highlights of New IC Groupings
Highlights of Special Authorization (SA) Criteria Changes

July 1, 2011 - Issue #62 PDF
Brief Summary of Drug Review Activities
Products Originally Reviewed via the Common Drug Review (CDR)
Osteoporosis
Products Not Added
Highlights of New Interchangeable (IC) Groupings

May 1, 2011 - Issue #61 PDF
Brief Summary of Drug Review Activities
Highlights of New Products Added
Highlights of New Interchangeable (IC) Groupings
Review of Benefit Status (ROBS) Process
Products Originally Reviewed via the Common Drug Review (CDR)

March 1, 2011 - Issue #60 PDF
Brief Summary of Drug Review Activities
Highlights of New Products Added
Highlights of New IC Groupings
Alzheimer's Disease SA Drug Products
Highlights of Special Authorization (SA) Criteria Changes
Did You Know...?

February 1, 2011 - Issue #59 PDF
Brief Summary of Drug Review Activities
Highlights of New Products Added
Special Authorization Criteria Changes

November 1, 2010 - Issue #58 PDF
Brief Summary of Drug Review Activities
Highlights of New Products Added
Special Authorization Criteria Changes

September 1, 2010 - Issue #57 PDF
Brief Summary of Drug Review Activities
Highlights of Products Added
Special Authorization Criteria Changes
Changes in Benefit Status
New IC Groupings
Products Originally Reviewed via the Common Drug Review (CDR)
Product Not Added

July 1, 2010 - Issue #56 PDF
Highlights of Products Added
Highlights of New IC Groupings
Highlights of Products Not Added
Products Originally Reviewed via the Common Drug Review (CDR)

April 1, 2010 - Issue #55 PDF
Highlights of New Products Added
Highlights of Coverage Criteria Changes
Highlights of Interchangeable Products Added
Highlights of Products Not Added
Change to Botox Unit of Issue
Reinstatement of Premarin Tablets
Orencia for Juvenile Idiopathic Arthritis
ROBS Review of Insulins and Oral Anti-Diabetic Agents
Fucithalmic De-Listed
Updated Price Policy
Expedited Review for Interchangeable Products & Revised Submission Requirements

October 1, 2009 - Issue #54 PDF
Highlights of Products Added
Highlights of Interchangeable Products Added
De-Listing of Premarin Tablets
Special Authorization Criteria Change for Avodart & Proscar

July 1, 2009 - Issue #53 PDF
Highlights of Products Added
Highlights of Interchangeable Products
Change in Benefit Status of Cyclobenzaprine 10 mg tablets
Highlights of Products Not Added

May 1, 2009 Update- Issue #52 PDF
Application of Least Cost Alternative to Gen-Clozapine 25 mg and 100 mg

April 1, 2009 - Issue #51 PDF
Highlights of Products Added
Highlights of Restricted Benefits Added
Highlights of Changes in Benefit Status or Coverage Criteria: Aggrenox, Aldara, Levetiracetam products, Humira, Rituxan, Biologics for RA and Chronic Hepatitis B drugs

January 1, 2009 - Issue #50 PDF
Highlights of New Products Added
Highlights of Products Not Added
Highlights of Special Authorization Products Added

October 1, 2008 - Issue #49 PDF
New Products Added
Interchangeable Products Added August 1, 2008
Products Not Added
Changes to Special Authorization Criteria for Medications Used in the Treatment of Alzheimer’s Disease

July 1, 2008 - Issue #48 PDF
Highlights of Products Not Added
Highlights of Changes to Benefit Status
Highlights of New Products Added
Highlights of Interchangeable Products Added May 1, 2008

April 1, 2008 - Issue #47 PDF
Highlights of New Products Added
Highlights of Products Not Added
Highlights of Changes to Benefit Status
Highlights of Interchageable Products Added February 1, 2008

January 1, 2008 - Issue #46PDF
Highlights of New Products Added
Highlights of Interchangeable Products Added
Highlights of Products Not Added
Special Authorization Criteria Change: Ketek

October 1, 2007 - Issue #45PDF
Highlights of New Products Added
Highlights of Special Authorization Products Added
Highlights of Interchangeable Products Added
Special Authorization Criteria Change: Aranesp and Eprex
Changes in Benefit Status: Glaucoma Treatments; Antiviral Agents

July 1, 2007 - Issue #44 PDF
Highlights of New Products Added
Highlights of Special Authorization Products Added
Highlights of Special Authorization Criteria Changes
Highlights of Products not Added
Changes in Benefit Status; Salbutamol 2 mg/mL (base) inhalation unit dose solutions, Eumovate topical cream

April 1, 2007 - Issue #43 PDF
Highlights of Products Added
Changes in Benefit Status of vaginal anti-infective products, parasympathomimetics, papaverine and Intron A
Highlights of Products Added via Special Authorization
Highlights of Products Not Added

January 1, 2007 - Issue #42 PDF
Highlights of Products Added
Highlights of Products Added via Special Authorization
Highlights of Products Added to MS Drug Coverage Program
Highlights of Products Not Added
Change in Benefit Status of Topical Antibiotic, EENT Antibiotic Products and Stemgen

October 1, 2006 - Issue #41 PDF
Highlights of Products Added
Highlights of Changes to Special Authorization Criteria
Highlights of Products Added via Special Authorization
Highlights of Products Not Added
Special Authorization Criteria Change for Drugs Used in the Treatment of Alzheimer's Disease

July 1, 2006 - Issue #40 PDF
Highlights of Products Added
Special Authorization Criteria Change for Duragesic Transdermal Patches Change in Benefit Status of EENT Anti-Allergy Products
Review of Benefit Status of Plavix
Highlights of Products Not Added
Removal of Interchangeability Designation of Novo-Bupropion SR 150 mg Tablets

April 1, 2006 - Issue #39 PDF
Highlights of New Products Added
Highlights of Interchangeable Products Added
Highlights of Products Not Added
New Criterion for Optional Special Authorization of Select Quinolones
Special Authorization Criteria Change for Alzheimer's Drugs

January 1, 2006 - Issue #38 PDF
Highlights of New Products Added
Highlights of Interchangeable Products Added
Highlights of Products Not Added
Topical Products Used in the Treatment of Acne
Optional Special Authorization (OSA)

October 1, 2005 - Issue #37 PDF
Highlights of New Products Added
Highlights of Interchangeable Products Added
Highlights of Special Authorization Criteria Changes
Neulasta Addition
Neupogen Criteria Change

July 1, 2005 - Issue #36 PDF
Highlights of New Products Added
Highlights of Special Authorization Criteria Changes
Highlights of Interchangeable Products Added
Review of Benefit Status (ROBS) Process
Common Drug Review Products

April 1, 2005 - Issue #35 PDF
Cancidas Added via Special Authorization
Highlights of New Products Added
Highlights of Products Not Added
Selective COX-2 Inhibitors: Emerging Safety Concerns
Bacid Removed from the ADBL

January 1, 2005 - Issue #34 PDF
Highlights from the Review of Antimicrobials
Highlights of Products Added
Additional Highlights

October 1, 2004 - Issue #33 PDF
Highlights of New Products Added
Highlights of Products Not Added
Products Removed from the ADBL
Pegetron Special Authorization Criteria

July 1, 2004 - Issue #32 PDF
Highlights of New Products Added
Highlights of Products Not Added
Enbrel for Polyarticular Juvenile Rheumatoid Arthritis
Changes to Special Authorization Coverage of Select Products for the Treatment of Hepatitis C

April 1, 2004 - Issue #31PDF
Highlights of New Products Added
Highlights of Interchangeable Products Added
Highlights of Products Not Added
Changes to Special Authorization Criteria for Drugs used in Alzheimer’s Disease
Changes to Special Authorization Criteria for Pegetron
The Rationale Behind Special Authorization (SA)

January 1, 2004 - Issue #30PDF
Highlights of Products Added via Special Authorization
Highlights of Products Added
Highlights of Products Not Added
Novo-Alendronate 10 mg tablets
Changes to Special Authorization Criteria for Actos

October 1, 2003 - Not issued

July 1, 2003 - Issue #29 PDF
Highlights of New Products Added
Highlights of Additional Strengths and Formulations of Products Available via Special Authorization
Highlights of Deferred Products
Highlights of Products Not Added
Products Designated as Interchangeable
Alberta Post-Marketing Study for Enbrel and Remicade

April 1, 2003 - Issue #28 PDF
Highlights of New Products Added
Highlights of Deferred Products
Highlights of Products Not Added
Changes to the Special Authorization Criteria for Nitoman
Changes to the Benefit Status of Detrol
Changes to the Special Authorization Criteria for Evista

January 1, 2003 - Issue #27 PDF
Highlights of New Products Added
Changes to the Benefit Status of Andriol
Highlights of Deferred Products
Highlights of Products Not Added
Highlights of Interchangeable Products added

October 1, 2002 - Update Issue #26 PDF
Flovent HFA Added

October 1, 2002 - Issue #25 PDF
Highlights of New Products Added
Highlights of Deferred Products
Highlights of Products Not Added
Devices Added to the ADBL as Restricted Benefit

July 1, 2002 - Issue #24 PDF
Highlights of New Products Added
Highlights of Deferred Products
Highlights of Products Not Added
Update: Status of TNF-Antagonists

April 1, 2002 - Issue #23 PDF
Highlights of New Products Added
Update: Removal of the LCA Policy from Methotrexate Sodium 25 mg/mL Preserved and Unpreserved Injectable Products
Highlights of Changes to SA Criteria
Highlights of Deferred Products
Highlights of Products Not Added

January 1, 2002 - Issue #22 PDF
Highlights of the Review of SA Drugs Used in the Treatment of Osteoporosis
Highlights of New Products Added
Highlights of Changes to SA Criteria
Highlights of Deferred Products
Interchangeability and Application of LCA to Methotrexate Sodium 25 mg/mL (base) Injection
Highlights of Products Not Added

Back to top

December 1, 2001 - Update PDF
Interchangeability of Warfarin Sodium Preparations

October 1, 2001 - Issue #21 PDF
Highlights of New Products Added
Highlights of New Products Added via Special Authorization (SA)
SA Criteria for Antiplatelet Agents
Highlights of Products Not Added

August 1, 2001 - Issue #20 PDF
Highlights of New Products Added via Special Authorization (SA)
Changes in SA Criteria
New LCA Products Added
Highlights of Products Deferred
Highlights of Products Not Added

April 1, 2001 - Issue #19 PDF
Highlights of New Products Added
Changes of Special Authorization (SA)
Highlights of Products Not Added
Expert Committee Profiles: Dr. Norman R.C. Campbell
Changes in SA Renewal Policy for Selected Products

January 1, 2001 - Issue #18 PDF
Products for Osteoporosis Added via Special Authorization
Products for Type 2 Diabetes Mellitus Added via Special Authorization
Additional Products Added via Special Authorization
Highlights of New Products Added
Highlights of Products Not Added

Back to top

December 1, 2000 - Update PDF
Interchangeability of Warfarin Sodium Preparations

October 1, 2000 - Issue #17 PDF
Changes in Special Authorization Criteria
Special Authorization for Cerezyme
Highlights of New Products Added
Expert Committee Profiles: Dr. Stephen C. Newman
Highlights of Deferred Products

July 1, 2000 - Issue #16 PDF
Change in Benefit Status
Highlights of New Products Added
Highlights of Deferred Products
Highlights of Products Not Added
Expert Committee Profiles: Dr. Judith Baker
Products Removed from the ADBL

April 1, 2000 - Issue #15 PDF
Highlights of New Products Added
Highlights of Deferred Products
Highlights of Products Not Added
Clarification on Aricept Special Authorization (SA) Criteria
Products Removed from the ADBL

January 1, 2000 - Issue #14 PDF
Highlights of New Products Added
Highlights of Deferred Products
Expert Committee Profiles: Dr. James Silvius
Why are drug products under review not eligible for special authorization or made available on an exception basis?

October 1, 1999 - Issue #13 PDF
Highlights of New Products 'Fast-Tracked'
New LCA Products Added
Highlights of Products Added and Not-Added

April 1, 1999 - Update PDF
Interchangeability of Levothyroxine Sodium Preparations

April 1, 1999 - Issue #12 PDF
Highlights of New Products Added
Highlights of Products Not Added

Back to top


NOTICE:
The DBL, DBS and related publications require knowledgeable interpretation and are intended primarily for professional health care practitioners, pharmacies, hospitals and organizations associated with the manufacture, distribution and use of pharmaceutical preparations.

Electronic versions of all DBL and DBS related publications are unofficial versions and are provided for convenience and private use only. Official paper versions can be obtained from Alberta Blue Cross who publishes them on behalf of Alberta Health and Wellness, Alberta Human Services, Children’s Services and Alberta Seniors (AISH).

Alberta Health and Wellness reserves the right to make changes, without notice, to the List through the Interactive DBL (iDBL), and any such changes to the Interactive DBL (iDBL) are effective the date of the change (unless otherwise stated) and regardless of the date of publication in the paper version or updates.